% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • drlongandstrong drlongandstrong Dec 20, 2012 3:15 PM Flag

    MRK's Tredaptive miss may benefit Amarin...details here

    Jefferies analyst Thomas Wei thinks so. According to Wei, Merck's report of Tredaptive missing its primary endpoint of showing cardiovascular benefit in its HPS2-THRIVE study might provide incremental benefit for Vascepa.

    Wei says Merck's failure may mean a shift from niacin therapies - such as Tredaptive or Abbott's Niaspan -- over to other therapy classes of cholestrol-lowering medicines like Vascepa.

    Sentiment: Strong Buy

2.80+0.01(+0.36%)Aug 31 4:00 PMEDT